AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT07009769
- Lead Sponsor
- Korea University Guro Hospital
- Brief Summary
The investigators aim to develop an AI-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 865
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic accuracy of the AI-based classification model using SERS signals from plasma-derived exosomes Retrospective, based on pre-collected samples through study completion, an average of 1 year To evaluate the diagnostic performance (sensitivity, specificity, and overall accuracy) of a machine learning model trained on SERS spectral data of plasma-derived exosomes in distinguishing lung cancer patients from healthy controls.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Korea University Guro Hospital
🇰🇷Guro-gu, Seoul, Korea, Republic of